A newly developed antibody called mimAb1, which mimics the function of a naturally occurring molecule called fibroblast growth factor 21, helped induce weight loss and improve insulin sensitivity and BMI in obese monkeys, researchers reported in Science Translational Medicine. However, researchers said it is still unclear how the treatment would work in human patients.